Article
TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics.
Molecular psychiatry - 1 Dec 2016
Gupta M, Neavin D, Liu D, Biernacka J, Hall-Flavin D, Bobo W V, Frye M A, Skime M, Jenkins G D, Batzler A, Kalari K, Matson W, Bhasin S S, Zhu H, Mushiroda T, Nakamura Y, Kubo M, Wang L, Kaddurah-Daouk R, Weinshilboum R M
Abstract excerpt
Millions of patients suffer from major depressive disorder (MDD), but many do not respond to selective serotonin reuptake inhibitor (SSRI) therapy. We used a pharmacometabolomics-informed pharmacogenomics research strategy to identify genes associated with metabolites that were related to SSRI response. Specifically, 306 MDD patients were treated with citalopram or escitalopram and blood was drawn at baseline, 4...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.